Orthocell secures key regulatory approval for Remplir in Singapore, paving way for ASEAN expansion

Orthocell secures key regulatory approval for Remplir in Singapore, paving way for ASEAN expansion

Orthocell, an Australian regenerative medicine company, has achieved a significant milestone with the receipt of major international regulatory approval for its nerve repair product Remplir from Singapore’s Health Sciences Authority (HSA). This regulatory clearance authorizes Orthocell to initiate sales in Singapore, marking the first international regulatory authorization for Remplir outside of Australia and New Zealand, […]